nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—pancreatic cancer—bile duct cancer	0.614	1	CtDrD
Erlotinib—EGFR—bile duct cancer	0.316	1	CbGaD
Erlotinib—ORM1—bile—bile duct cancer	0.00373	0.148	CbGeAlD
Erlotinib—Vandetanib—EGFR—bile duct cancer	0.00115	0.513	CrCbGaD
Erlotinib—Gefitinib—EGFR—bile duct cancer	0.00109	0.487	CrCbGaD
Erlotinib—ORM1—gall bladder—bile duct cancer	0.00103	0.0411	CbGeAlD
Erlotinib—NR1I2—liver—bile duct cancer	0.000992	0.0394	CbGeAlD
Erlotinib—ALB—gall bladder—bile duct cancer	0.000907	0.036	CbGeAlD
Erlotinib—PIP4K2C—pancreas—bile duct cancer	0.000889	0.0353	CbGeAlD
Erlotinib—LTK—lymph node—bile duct cancer	0.000761	0.0302	CbGeAlD
Erlotinib—SLK—pancreas—bile duct cancer	0.000756	0.03	CbGeAlD
Erlotinib—TNK1—liver—bile duct cancer	0.000728	0.0289	CbGeAlD
Erlotinib—AURKC—lymph node—bile duct cancer	0.000657	0.0261	CbGeAlD
Erlotinib—FLT3—liver—bile duct cancer	0.000626	0.0248	CbGeAlD
Erlotinib—JAK3—lymph node—bile duct cancer	0.000608	0.0241	CbGeAlD
Erlotinib—ABL2—liver—bile duct cancer	0.000598	0.0237	CbGeAlD
Erlotinib—EGFR—liver—bile duct cancer	0.000583	0.0232	CbGeAlD
Erlotinib—PIP4K2C—liver—bile duct cancer	0.000565	0.0224	CbGeAlD
Erlotinib—TNK1—lymph node—bile duct cancer	0.000559	0.0222	CbGeAlD
Erlotinib—ULK3—liver—bile duct cancer	0.00054	0.0214	CbGeAlD
Erlotinib—MKNK1—liver—bile duct cancer	0.000508	0.0202	CbGeAlD
Erlotinib—SLK—liver—bile duct cancer	0.000481	0.0191	CbGeAlD
Erlotinib—FLT3—lymph node—bile duct cancer	0.00048	0.019	CbGeAlD
Erlotinib—ABL2—lymph node—bile duct cancer	0.000458	0.0182	CbGeAlD
Erlotinib—ABL1—pancreas—bile duct cancer	0.000453	0.018	CbGeAlD
Erlotinib—EGFR—lymph node—bile duct cancer	0.000447	0.0178	CbGeAlD
Erlotinib—PIP4K2C—lymph node—bile duct cancer	0.000433	0.0172	CbGeAlD
Erlotinib—STK10—liver—bile duct cancer	0.000418	0.0166	CbGeAlD
Erlotinib—ULK3—lymph node—bile duct cancer	0.000414	0.0164	CbGeAlD
Erlotinib—UGT1A1—liver—bile duct cancer	0.000395	0.0157	CbGeAlD
Erlotinib—MKNK1—lymph node—bile duct cancer	0.00039	0.0155	CbGeAlD
Erlotinib—MAP2K5—liver—bile duct cancer	0.000374	0.0148	CbGeAlD
Erlotinib—SLK—lymph node—bile duct cancer	0.000369	0.0146	CbGeAlD
Erlotinib—STK10—lymph node—bile duct cancer	0.000321	0.0127	CbGeAlD
Erlotinib—ORM1—liver—bile duct cancer	0.000303	0.012	CbGeAlD
Erlotinib—SLCO2B1—liver—bile duct cancer	0.000291	0.0115	CbGeAlD
Erlotinib—ABL1—liver—bile duct cancer	0.000288	0.0114	CbGeAlD
Erlotinib—MAP2K5—lymph node—bile duct cancer	0.000286	0.0114	CbGeAlD
Erlotinib—ALB—liver—bile duct cancer	0.000266	0.0106	CbGeAlD
Erlotinib—CYP3A5—pancreas—bile duct cancer	0.000265	0.0105	CbGeAlD
Erlotinib—CYP1B1—liver—bile duct cancer	0.000244	0.00969	CbGeAlD
Erlotinib—ORM1—lymph node—bile duct cancer	0.000233	0.00923	CbGeAlD
Erlotinib—SLCO2B1—lymph node—bile duct cancer	0.000223	0.00885	CbGeAlD
Erlotinib—ABL1—lymph node—bile duct cancer	0.000221	0.00877	CbGeAlD
Erlotinib—ALB—lymph node—bile duct cancer	0.000204	0.0081	CbGeAlD
Erlotinib—CYP1B1—lymph node—bile duct cancer	0.000187	0.00743	CbGeAlD
Erlotinib—CYP2C8—liver—bile duct cancer	0.000187	0.00742	CbGeAlD
Erlotinib—ABCG2—liver—bile duct cancer	0.000182	0.00722	CbGeAlD
Erlotinib—CYP1A2—liver—bile duct cancer	0.000175	0.00694	CbGeAlD
Erlotinib—CYP1A1—liver—bile duct cancer	0.000173	0.00685	CbGeAlD
Erlotinib—CYP3A5—liver—bile duct cancer	0.000169	0.0067	CbGeAlD
Erlotinib—ABCB1—pancreas—bile duct cancer	0.000141	0.00559	CbGeAlD
Erlotinib—ABCG2—lymph node—bile duct cancer	0.000139	0.00553	CbGeAlD
Erlotinib—CYP1A1—lymph node—bile duct cancer	0.000132	0.00525	CbGeAlD
Erlotinib—CYP3A4—liver—bile duct cancer	0.000127	0.00503	CbGeAlD
Erlotinib—CYP2D6—liver—bile duct cancer	0.000125	0.00495	CbGeAlD
Erlotinib—ABCB1—liver—bile duct cancer	8.96e-05	0.00356	CbGeAlD
Erlotinib—ABCB1—lymph node—bile duct cancer	6.87e-05	0.00273	CbGeAlD
Erlotinib—EGFR—Signaling by ERBB4—IL6—bile duct cancer	1.74e-05	0.00041	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—HRAS—bile duct cancer	1.74e-05	0.000409	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—SMAD4—bile duct cancer	1.73e-05	0.000407	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—HRAS—bile duct cancer	1.73e-05	0.000407	CbGpPWpGaD
Erlotinib—EGFR—EGF/EGFR Signaling Pathway—HRAS—bile duct cancer	1.73e-05	0.000407	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—FAR2—bile duct cancer	1.73e-05	0.000406	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—HRAS—bile duct cancer	1.72e-05	0.000405	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—HRAS—bile duct cancer	1.71e-05	0.000403	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—MMP2—bile duct cancer	1.7e-05	0.0004	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—bile duct cancer	1.69e-05	0.000397	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—IDH1—bile duct cancer	1.68e-05	0.000395	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—KRAS—bile duct cancer	1.68e-05	0.000395	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—IL6—bile duct cancer	1.66e-05	0.000391	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—TP53—bile duct cancer	1.66e-05	0.000391	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—IL6—bile duct cancer	1.66e-05	0.00039	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—IL6—bile duct cancer	1.65e-05	0.000388	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—IL6—bile duct cancer	1.64e-05	0.000386	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	1.63e-05	0.000383	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—bile duct cancer	1.62e-05	0.000382	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—HRAS—bile duct cancer	1.61e-05	0.000379	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—HRAS—bile duct cancer	1.61e-05	0.000379	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—HRAS—bile duct cancer	1.61e-05	0.000379	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—HRAS—bile duct cancer	1.6e-05	0.000376	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—HRAS—bile duct cancer	1.59e-05	0.000374	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—NRAS—bile duct cancer	1.59e-05	0.000374	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	1.59e-05	0.000373	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—HRAS—bile duct cancer	1.58e-05	0.000372	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—HRAS—bile duct cancer	1.58e-05	0.000371	CbGpPWpGaD
Erlotinib—ALB—Selenium Micronutrient Network—IL6—bile duct cancer	1.55e-05	0.000366	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—IL6—bile duct cancer	1.54e-05	0.000363	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—bile duct cancer	1.54e-05	0.000363	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—IL6—bile duct cancer	1.54e-05	0.000363	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—MMP9—bile duct cancer	1.53e-05	0.00036	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—IL6—bile duct cancer	1.53e-05	0.00036	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—HRAS—bile duct cancer	1.52e-05	0.000358	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—IL6—bile duct cancer	1.52e-05	0.000356	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—IL6—bile duct cancer	1.51e-05	0.000355	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—NRAS—bile duct cancer	1.5e-05	0.000353	CbGpPWpGaD
Erlotinib—JAK3—Immune System—ERBB2—bile duct cancer	1.5e-05	0.000352	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—HRAS—bile duct cancer	1.49e-05	0.000351	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—ERBB2—bile duct cancer	1.49e-05	0.000351	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TGFBR2—bile duct cancer	1.49e-05	0.000351	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—SLC5A5—bile duct cancer	1.46e-05	0.000344	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—MMP2—bile duct cancer	1.45e-05	0.000342	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—EGFR—bile duct cancer	1.45e-05	0.000341	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—GNAS—bile duct cancer	1.44e-05	0.000338	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—bile duct cancer	1.43e-05	0.000336	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—SMAD4—bile duct cancer	1.41e-05	0.000332	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—IDH2—bile duct cancer	1.4e-05	0.000329	CbGpPWpGaD
Erlotinib—MKNK1—Disease—NRAS—bile duct cancer	1.4e-05	0.000328	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—bile duct cancer	1.38e-05	0.000325	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—bile duct cancer	1.38e-05	0.000324	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—KRAS—bile duct cancer	1.37e-05	0.000322	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—bile duct cancer	1.37e-05	0.000321	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—NRAS—bile duct cancer	1.36e-05	0.00032	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bile duct cancer	1.35e-05	0.000316	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—FAR2—bile duct cancer	1.33e-05	0.000314	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HGF—bile duct cancer	1.33e-05	0.000313	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—IDH2—bile duct cancer	1.32e-05	0.000311	CbGpPWpGaD
Erlotinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—bile duct cancer	1.32e-05	0.000311	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—ERBB2—bile duct cancer	1.32e-05	0.00031	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—GNAS—bile duct cancer	1.31e-05	0.000308	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—SLC5A5—bile duct cancer	1.31e-05	0.000307	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—GNAS—bile duct cancer	1.31e-05	0.000307	CbGpPWpGaD
Erlotinib—MKNK1—Disease—TGFB1—bile duct cancer	1.3e-05	0.000305	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—KRAS—bile duct cancer	1.29e-05	0.000304	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—ERBB2—bile duct cancer	1.28e-05	0.000302	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—SLC5A5—bile duct cancer	1.28e-05	0.000301	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—MMP9—bile duct cancer	1.28e-05	0.000301	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—ERBB2—bile duct cancer	1.27e-05	0.0003	CbGpPWpGaD
Erlotinib—MKNK1—Disease—EGFR—bile duct cancer	1.27e-05	0.000299	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—HGF—bile duct cancer	1.25e-05	0.000294	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—NRAS—bile duct cancer	1.25e-05	0.000293	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—SLC5A5—bile duct cancer	1.22e-05	0.000287	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—IDH2—bile duct cancer	1.21e-05	0.000285	CbGpPWpGaD
Erlotinib—ALB—Metabolism—IDH2—bile duct cancer	1.21e-05	0.000284	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—IDH1—bile duct cancer	1.2e-05	0.000283	CbGpPWpGaD
Erlotinib—MKNK1—Disease—KRAS—bile duct cancer	1.2e-05	0.000283	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—KRAS—bile duct cancer	1.17e-05	0.000275	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—HRAS—bile duct cancer	1.16e-05	0.000274	CbGpPWpGaD
Erlotinib—EGFR—Disease—TGFBR2—bile duct cancer	1.14e-05	0.000269	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	1.14e-05	0.000269	CbGpPWpGaD
Erlotinib—JAK3—Immune System—NRAS—bile duct cancer	1.14e-05	0.000268	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—IDH1—bile duct cancer	1.14e-05	0.000268	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HGF—bile duct cancer	1.14e-05	0.000267	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—EGFR—bile duct cancer	1.14e-05	0.000267	CbGpPWpGaD
Erlotinib—ALB—Transmembrane transport of small molecules—GNAS—bile duct cancer	1.14e-05	0.000267	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—NRAS—bile duct cancer	1.13e-05	0.000267	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—ERBB2—bile duct cancer	1.13e-05	0.000265	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—IL6—bile duct cancer	1.11e-05	0.000262	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—NRAS—bile duct cancer	1.11e-05	0.000262	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—SLC5A5—bile duct cancer	1.11e-05	0.000261	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MMP9—bile duct cancer	1.1e-05	0.000259	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—HRAS—bile duct cancer	1.1e-05	0.000258	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—MMP9—bile duct cancer	1.09e-05	0.000257	CbGpPWpGaD
Erlotinib—EGFR—Disease—SMAD4—bile duct cancer	1.08e-05	0.000254	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—ERBB2—bile duct cancer	1.08e-05	0.000254	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—KRAS—bile duct cancer	1.07e-05	0.000253	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—IDH2—bile duct cancer	1.06e-05	0.000249	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—TGFB1—bile duct cancer	1.05e-05	0.000248	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—IL6—bile duct cancer	1.05e-05	0.000247	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—IDH1—bile duct cancer	1.04e-05	0.000245	CbGpPWpGaD
Erlotinib—JAK3—Immune System—EGFR—bile duct cancer	1.04e-05	0.000244	CbGpPWpGaD
Erlotinib—ALB—Metabolism—IDH1—bile duct cancer	1.04e-05	0.000244	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TGFB1—bile duct cancer	1.03e-05	0.000243	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—EGFR—bile duct cancer	1.03e-05	0.000243	CbGpPWpGaD
Erlotinib—MKNK1—Disease—HRAS—bile duct cancer	1.02e-05	0.00024	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—GNAS—bile duct cancer	1.02e-05	0.000239	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—NRAS—bile duct cancer	1e-05	0.000236	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—IDH2—bile duct cancer	9.96e-06	0.000234	CbGpPWpGaD
Erlotinib—ABCB1—Transmembrane transport of small molecules—GNAS—bile duct cancer	9.95e-06	0.000234	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—HRAS—bile duct cancer	9.94e-06	0.000234	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—TGFB1—bile duct cancer	9.88e-06	0.000232	CbGpPWpGaD
Erlotinib—JAK3—Immune System—KRAS—bile duct cancer	9.81e-06	0.000231	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—NRAS—bile duct cancer	9.77e-06	0.00023	CbGpPWpGaD
Erlotinib—MKNK1—Disease—IL6—bile duct cancer	9.77e-06	0.00023	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—KRAS—bile duct cancer	9.77e-06	0.00023	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—bile duct cancer	9.73e-06	0.000229	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—NRAS—bile duct cancer	9.7e-06	0.000228	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—ERBB2—bile duct cancer	9.69e-06	0.000228	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—KRAS—bile duct cancer	9.58e-06	0.000225	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—NOS2—bile duct cancer	9.58e-06	0.000225	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bile duct cancer	9.54e-06	0.000224	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—IL6—bile duct cancer	9.51e-06	0.000224	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—GNAS—bile duct cancer	9.47e-06	0.000223	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—EGFR—bile duct cancer	9.13e-06	0.000215	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—HRAS—bile duct cancer	9.13e-06	0.000215	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—IDH1—bile duct cancer	9.09e-06	0.000214	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TGFB1—bile duct cancer	9.08e-06	0.000214	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—TGFB1—bile duct cancer	9.01e-06	0.000212	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—bile duct cancer	9.01e-06	0.000212	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—EGFR—bile duct cancer	8.91e-06	0.000209	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—IL6—bile duct cancer	8.74e-06	0.000205	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—KRAS—bile duct cancer	8.62e-06	0.000203	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—GNAS—bile duct cancer	8.62e-06	0.000203	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—NRAS—bile duct cancer	8.56e-06	0.000201	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—IDH1—bile duct cancer	8.56e-06	0.000201	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—bile duct cancer	8.51e-06	0.0002	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—IDH2—bile duct cancer	8.44e-06	0.000198	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—KRAS—bile duct cancer	8.41e-06	0.000198	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—KRAS—bile duct cancer	8.34e-06	0.000196	CbGpPWpGaD
Erlotinib—JAK3—Immune System—HRAS—bile duct cancer	8.34e-06	0.000196	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MMP9—bile duct cancer	8.31e-06	0.000195	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—HRAS—bile duct cancer	8.3e-06	0.000195	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—NRAS—bile duct cancer	8.22e-06	0.000193	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—HRAS—bile duct cancer	8.14e-06	0.000192	CbGpPWpGaD
Erlotinib—EGFR—Disease—NOS2—bile duct cancer	8.05e-06	0.000189	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bile duct cancer	8.01e-06	0.000188	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TGFBR2—bile duct cancer	8e-06	0.000188	CbGpPWpGaD
Erlotinib—JAK3—Immune System—IL6—bile duct cancer	7.98e-06	0.000188	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—IL6—bile duct cancer	7.94e-06	0.000187	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—SLC5A5—bile duct cancer	7.94e-06	0.000187	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—ERBB2—bile duct cancer	7.9e-06	0.000186	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—GNAS—bile duct cancer	7.72e-06	0.000181	CbGpPWpGaD
Erlotinib—ABL1—Immune System—ERBB2—bile duct cancer	7.67e-06	0.00018	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—SMAD4—bile duct cancer	7.57e-06	0.000178	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—SLC5A5—bile duct cancer	7.51e-06	0.000177	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—bile duct cancer	7.48e-06	0.000176	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—NRAS—bile duct cancer	7.37e-06	0.000173	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—KRAS—bile duct cancer	7.37e-06	0.000173	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—HRAS—bile duct cancer	7.33e-06	0.000172	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—IDH1—bile duct cancer	7.25e-06	0.000171	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—HRAS—bile duct cancer	7.15e-06	0.000168	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—HRAS—bile duct cancer	7.09e-06	0.000167	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—KRAS—bile duct cancer	7.08e-06	0.000166	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	7.03e-06	0.000165	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—IL6—bile duct cancer	7.02e-06	0.000165	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—SLC5A5—bile duct cancer	6.88e-06	0.000162	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TGFB1—bile duct cancer	6.85e-06	0.000161	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IL6—bile duct cancer	6.84e-06	0.000161	CbGpPWpGaD
Erlotinib—ALB—Metabolism—SLC5A5—bile duct cancer	6.84e-06	0.000161	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—IL6—bile duct cancer	6.79e-06	0.00016	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MMP9—bile duct cancer	6.77e-06	0.000159	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—EGFR—bile duct cancer	6.72e-06	0.000158	CbGpPWpGaD
Erlotinib—EGFR—Immune System—ERBB2—bile duct cancer	6.56e-06	0.000154	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—IDH2—bile duct cancer	6.51e-06	0.000153	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	6.45e-06	0.000152	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	6.41e-06	0.000151	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KRAS—bile duct cancer	6.34e-06	0.000149	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—HRAS—bile duct cancer	6.26e-06	0.000147	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—GNAS—bile duct cancer	6.17e-06	0.000145	CbGpPWpGaD
Erlotinib—EGFR—Disease—ERBB2—bile duct cancer	6.05e-06	0.000142	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—HRAS—bile duct cancer	6.02e-06	0.000141	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—NRAS—bile duct cancer	6.01e-06	0.000141	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—IL6—bile duct cancer	6e-06	0.000141	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—SLC5A5—bile duct cancer	5.99e-06	0.000141	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTGS2—bile duct cancer	5.92e-06	0.000139	CbGpPWpGaD
Erlotinib—ABL1—Immune System—NRAS—bile duct cancer	5.84e-06	0.000137	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—GNAS—bile duct cancer	5.83e-06	0.000137	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—SLC5A5—bile duct cancer	5.65e-06	0.000133	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—bile duct cancer	5.64e-06	0.000133	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—IDH1—bile duct cancer	5.6e-06	0.000132	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TGFB1—bile duct cancer	5.58e-06	0.000131	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—NRAS—bile duct cancer	5.48e-06	0.000129	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—EGFR—bile duct cancer	5.47e-06	0.000129	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—NRAS—bile duct cancer	5.46e-06	0.000128	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTGS2—bile duct cancer	5.45e-06	0.000128	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—HRAS—bile duct cancer	5.39e-06	0.000127	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—GNAS—bile duct cancer	5.35e-06	0.000126	CbGpPWpGaD
Erlotinib—ABL1—Immune System—EGFR—bile duct cancer	5.32e-06	0.000125	CbGpPWpGaD
Erlotinib—ALB—Metabolism—GNAS—bile duct cancer	5.32e-06	0.000125	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KRAS—bile duct cancer	5.17e-06	0.000122	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IL6—bile duct cancer	5.16e-06	0.000121	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TGFB1—bile duct cancer	5.09e-06	0.00012	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTGS2—bile duct cancer	5.09e-06	0.00012	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KRAS—bile duct cancer	5.02e-06	0.000118	CbGpPWpGaD
Erlotinib—EGFR—Immune System—NRAS—bile duct cancer	4.99e-06	0.000117	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—SLC5A5—bile duct cancer	4.79e-06	0.000113	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—KRAS—bile duct cancer	4.72e-06	0.000111	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—KRAS—bile duct cancer	4.7e-06	0.00011	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—GNAS—bile duct cancer	4.66e-06	0.00011	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—bile duct cancer	4.63e-06	0.000109	CbGpPWpGaD
Erlotinib—EGFR—Disease—NRAS—bile duct cancer	4.6e-06	0.000108	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—bile duct cancer	4.6e-06	0.000108	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	4.48e-06	0.000105	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—HRAS—bile duct cancer	4.4e-06	0.000103	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—GNAS—bile duct cancer	4.39e-06	0.000103	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KRAS—bile duct cancer	4.29e-06	0.000101	CbGpPWpGaD
Erlotinib—EGFR—Disease—TGFB1—bile duct cancer	4.28e-06	0.000101	CbGpPWpGaD
Erlotinib—ABL1—Immune System—HRAS—bile duct cancer	4.27e-06	0.0001	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—ERBB2—bile duct cancer	4.24e-06	9.97e-05	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IL6—bile duct cancer	4.21e-06	9.9e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—bile duct cancer	4.19e-06	9.86e-05	CbGpPWpGaD
Erlotinib—ABL1—Immune System—IL6—bile duct cancer	4.09e-06	9.61e-05	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—HRAS—bile duct cancer	4.01e-06	9.43e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—HRAS—bile duct cancer	3.99e-06	9.39e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—KRAS—bile duct cancer	3.96e-06	9.32e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—IL6—bile duct cancer	3.82e-06	8.99e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—GNAS—bile duct cancer	3.72e-06	8.75e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—SLC5A5—bile duct cancer	3.69e-06	8.69e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—HRAS—bile duct cancer	3.65e-06	8.58e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MMP9—bile duct cancer	3.64e-06	8.55e-05	CbGpPWpGaD
Erlotinib—EGFR—Immune System—IL6—bile duct cancer	3.49e-06	8.21e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—HRAS—bile duct cancer	3.37e-06	7.92e-05	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—bile duct cancer	3.32e-06	7.8e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—NRAS—bile duct cancer	3.22e-06	7.58e-05	CbGpPWpGaD
Erlotinib—EGFR—Disease—IL6—bile duct cancer	3.22e-06	7.58e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—bile duct cancer	3.13e-06	7.37e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TGFB1—bile duct cancer	3e-06	7.05e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—bile duct cancer	2.87e-06	6.75e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—GNAS—bile duct cancer	2.87e-06	6.75e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—bile duct cancer	2.86e-06	6.71e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KRAS—bile duct cancer	2.78e-06	6.53e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—bile duct cancer	2.5e-06	5.88e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—bile duct cancer	2.47e-06	5.8e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—HRAS—bile duct cancer	2.36e-06	5.55e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—bile duct cancer	2.36e-06	5.54e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IL6—bile duct cancer	2.26e-06	5.31e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—bile duct cancer	2e-06	4.7e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—bile duct cancer	1.54e-06	3.62e-05	CbGpPWpGaD
